...
首页> 外文期刊>Mediators of inflammation >Serum Amyloid Alpha in Parapneumonic Effusions
【24h】

Serum Amyloid Alpha in Parapneumonic Effusions

机译:肺炎旁肺积液中的血清淀粉样蛋白

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Study objectives. To assess serum amyloid alpha (SAA) pleural fluid levels in parapneumonic effusion (PPE) and to investigate SAA diagnostic performance in PPE diagnosis and outcome. Methods. We studied prospectively 57 consecutive patients with PPE (empyema (EMP), complicated (CPE), and uncomplicated parapneumonic effusion (UPE)). SAA, CRP, TNF-alpha, IL-1beta, and IL-6 levels were evaluated in serum and pleural fluid at baseline. Patients were followed for 6-months to detect pleural thickening/loculations. Results. Pleural SAA levels (mg/dL) median(IQR) were significantly higher in CPE compared to UPE (P < 0.04); CRP levels were higher in EMP and CPE compared to UPE (P < 0.01). There was no significant difference between IL-1beta, IL-6, TNF-alpha level in different PPE forms. No significant association between SAA levels and 6-month outcome was found. At 6-months, patients with no evidence of loculations/thickening had significantly higher pleural fluid pH, glucose levels (P = 0.03), lower LDH (P = 0.005), IL-1beta levels (P = 0.001) compared to patients who presented pleural loculations/thickening. Conclusions. SAA is increased in complicated PPE, and it might be useful as a biomarker for UPE and CPE diagnosis. SAA levels did not demonstrate considerable diagnostic performance in identifying patients who develop pleural thickening/loculations after a PPE.
机译:学习目标。评估肺炎旁肺积液(PPE)中的血清淀粉样蛋白α(SAA)胸膜液水平,并调查SAA在PPE诊断和预后中的诊断性能。方法。我们前瞻性研究了57名连续性PPE患者(肺气肿(EMP),复杂性(CPE)和单纯性肺炎旁肺积液(UPE))。在基线时评估血清和胸腔积液中的SAA,CRP,TNF-α,IL-1beta和IL-6水平。随访患者6个月,以检测胸膜增厚/位置。结果。与UPE相比,CPE中的胸膜SAA水平(mg / dL)中位数(IQR)显着更高(P <0.04);与UPE相比,EMP和CPE中的CRP水平更高(P <0.01)。在不同的PPE形式中,IL-1beta,IL-6,TNF-α水平之间没有显着差异。 SAA水平与6个月预后之间无显着关联。与出现这种情况的患者相比,在6个月时,没有定位/增厚迹象的患者的胸水pH,葡萄糖水平(P = 0.03),LDH(P = 0.005),IL-1beta水平(P = 0.001)明显更高。胸膜位置/增厚。结论。复杂的PPE中SAA会增加,它可能用作UPE和CPE诊断的生物标志物。 SAA水平在确定PPE后出现胸膜增厚/定位的患者中并未显示出可观的诊断性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号